undamentalytics Newsletter
Sign in

Vistagen Therapeutics, Inc. balance sheet

At the end of fiscal 2026, Vistagen Therapeutics, Inc. had total assets of $48.6m, total liabilities of $13.0m and shareholders' equity of $35.5m. It held $30.8m in cash against $96,000 of debt.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Mar 20112012Mar 20122013Mar 20132016Mar 20162017Mar 20172018Mar 20182020Mar 20202021Mar 20212022Mar 20222023Mar 20232024Mar 20242025Mar 20252026Mar 2026LTMJun 2026
Cash and equivalents001031011036817119673117
Receivables00—0——————————
Total current assets010131121047118121824734
Total assets010141161087521124844936
Accounts payable21211121322121
Deferred revenue (current)——————01111320
Total current liabilities1125211284655131311
Long-term debt———0000———————
Total debt00000000000000
Total liabilities19131343412161099141311
Shareholders' equity−33−6−13−317−6926512114703624
Non-controlling interests and other (assets − liabilities − equity)15−7−0———————————
Shares outstanding—150m————————————

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: KRRO vs VTGNCLGN vs VTGNUPB vs VTGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Vistagen Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Vistagen Therapeutics, Inc.